{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T14:55:34Z","timestamp":1703343334633},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T00:00:00Z","timestamp":1444003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1007\/s12282-015-0642-7","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T07:07:11Z","timestamp":1444028831000},"page":"789-796","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Magnetic resonance examination to predict pathological complete response following neoadjuvant chemotherapy: when is it appropriate for HER2-positive and triple-negative breast cancers?"],"prefix":"10.1007","volume":"23","author":[{"given":"Satoko","family":"Okamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihide","family":"Kanemaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Tsugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,10,5]]},"reference":[{"key":"642_CR1","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672\u201385.","journal-title":"J Clin Oncol"},{"key":"642_CR2","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1200\/JCO.2007.15.0235","volume":"26","author":"P Rastogi","year":"2008","unstructured":"Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778\u201385.","journal-title":"J Clin Oncol"},{"key":"642_CR3","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1200\/JCO.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414\u201322.","journal-title":"J Clin Oncol"},{"key":"642_CR4","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"30","author":"G Minckwitz Von","year":"2012","unstructured":"Von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796\u2013804.","journal-title":"J Clin Oncol"},{"key":"642_CR5","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.2010.31.1258","volume":"29","author":"CE Loo","year":"2011","unstructured":"Loo CE, Straver ME, Rodenhuis S, Muller SH, Wesseling J, Vrancken Peeters MJ, et al. Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. J Clin Oncol. 2011;29:660\u20139.","journal-title":"J Clin Oncol"},{"key":"642_CR6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2214\/AJR.07.3567","volume":"191","author":"CE Loo","year":"2008","unstructured":"Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR. 2008;191:1331\u20138.","journal-title":"AJR"},{"key":"642_CR7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1148\/radiol.12110748","volume":"263","author":"NM Hylton","year":"2012","unstructured":"Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy\u2014results from ACRIN 6657\/I-SPY TRIAL. Radiology. 2012;263:663\u201372.","journal-title":"Radiology"},{"key":"642_CR8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.2214\/ajr.184.6.01841774","volume":"184","author":"SC Partridge","year":"2005","unstructured":"Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, et al. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR. 2005;184:1774\u201381.","journal-title":"AJR"},{"key":"642_CR9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1148\/radiol.13121801","volume":"268","author":"Ann Yi","year":"2013","unstructured":"Yi Ann, Cho Nariya, Im Seock-Ah, Chang JM, Kim SJ, Moon HG, et al. Survival outcomes of breast cancer patients who receive neoadjuvant chemotherapy: association with dynamic contrast-enhanced MR imaging with computer-aided evaluation. Radiology. 2013;268:662\u201372.","journal-title":"Radiology"},{"key":"642_CR10","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1200\/JCO.2005.07.032","volume":"23","author":"AU Buzdar","year":"2005","unstructured":"Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant chemotherapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005;23:3676\u201385.","journal-title":"J Clin Oncol"},{"key":"642_CR11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","volume":"13","author":"AU Buzdar","year":"2007","unstructured":"Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, et al. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 2007;13:228\u201333.","journal-title":"Clin Cancer Res"},{"key":"642_CR12","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2009.23.8451","volume":"28","author":"M Untch","year":"2010","unstructured":"Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010;28:2024\u201331.","journal-title":"J Clin Oncol"},{"key":"642_CR13","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1200\/JCO.2008.21.4163","volume":"27","author":"WM Sikov","year":"2009","unstructured":"Sikov WM, Dizon DS, Strenger R, Legare RD, Theall KP, Graves TA, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a Brown University Oncology Group Study. J Clin Oncol. 2009;27:3693\u2013700.","journal-title":"J Clin Oncol"},{"key":"642_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"642_CR15","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/tbj.12124","volume":"19","author":"GS Sonke","year":"2013","unstructured":"Sonke GS, Mandjes IA, Holtkamp MJ, Schot M, van Werkhoven E, Wesseling J, et al. Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer. Breast J. 2013;19:419\u201326.","journal-title":"Breast J"},{"key":"642_CR16","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/02841860802060844","volume":"47","author":"S Paluch-Shimon","year":"2008","unstructured":"Paluch-Shimon S, Wolf I, Goldberg Evron E, Papa MZ, Shabtai M, et al. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer. Acta Oncol. 2008;47:1564\u20139.","journal-title":"Acta Oncol"},{"key":"642_CR17","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10549-010-1228-x","volume":"125","author":"G Minckwitz Von","year":"2011","unstructured":"Von Minckwitz G, Untch M, Nuesch E, Schot M, van Werkhoven E, Wesseling J, et al. Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat. 2011;125:145\u201356.","journal-title":"Breast Cancer Res Treat"},{"key":"642_CR18","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1200\/JCO.2009.23.8303","volume":"28","author":"G Minckwitz Von","year":"2010","unstructured":"Von Minckwitz G, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28:2015\u201323.","journal-title":"J Clin Oncol"},{"key":"642_CR19","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, Fasching PA, Huober J, Tesch H, et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2\u2013overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol. 2011;29:3351\u20137.","journal-title":"J Clin Oncol"},{"key":"642_CR20","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1470-2045(11)70397-7","volume":"13","author":"M Untch","year":"2012","unstructured":"Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer JU, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135\u201344.","journal-title":"Lancet Oncol"},{"key":"642_CR21","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10549-010-0939-3","volume":"122","author":"JY Pierga","year":"2010","unstructured":"Pierga JY, Delaloge S, Espi\u00e9 M, Brain E, Sigal-Zafrani B, Mathieu MC, et al. A multicenter randomized phase II study of sequential epirubicin\/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat. 2010;122:429\u201337.","journal-title":"Breast Cancer Res Treat"},{"key":"642_CR22","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.clbc.2014.12.003","volume":"15","author":"S Tanaka","year":"2015","unstructured":"Tanaka S, Iwamoto M, Kimura K, Matsunami N, Morishima H, Yoshidome K, et al. Phase II study of neoadjuvant anthracycline-based regimens combined with nanoparticle albumin-bound paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive operable breast cancer. Clin Breast Cancer. 2015;15:191\u20136.","journal-title":"Clin Breast Cancer"},{"key":"642_CR23","first-page":"4665","volume":"30","author":"T Shimizu","year":"2010","unstructured":"Shimizu T, Hirano A, Kamimura M, Ogura K, Kim N, Watanabe O, et al. A phase II study of epirubicin and cyclophosphamide followed by weekly paclitaxel with or without trastuzumab as primary systemic therapy in locally advanced breast cancer. Anticancer Res. 2010;30:4665\u201371.","journal-title":"Anticancer Res"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-015-0642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12282-015-0642-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-015-0642-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T12:40:59Z","timestamp":1559565659000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12282-015-0642-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,5]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1007\/s12282-015-0642-7","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,5]]}}}